Trial reportInternational wound journal2022
Clinical efficacy of chitosan-based hydrocolloid dressing in the treatment of chronic refractory wounds.
Trial report in International wound journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Clinical efficacy of chitosan-based hydrocolloid dressing in the treatment of chronic refractory wounds.International wound journal · 2022Trial
- Recent Applications of Chitosan-Based Biomaterials as Wound Dressings.International journal of molecular sciences · 2026Review
- Distribution and Antibiotic Resistance Characteristics of Pathogenic Bacteria in Chronic Wound Infections: A Five-Year Retrospective Study at a Tertiary Hospital.Infection and drug resistance · 2026Article
- Diabetic Wound Healing: Mechanism and Treatment Strategies with a Special Focus on Angiogenesis.Current drug research reviews · 2026Review
- From Sea to Therapy: Marine Biomaterials for Drug Delivery and Wound Healing.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Progress of microneedle targeted modulation technology in the reconstruction of immune microenvironment in diabetic wounds.European journal of medical research · 2025Review
- Prevalence and Mechanisms of Itch in Chronic Wounds: A Narrative Review.Journal of clinical medicine · 2025Review
- Advanced biomaterials in pressure ulcer prevention and care: from basic research to clinical practice.Frontiers in bioengineering and biotechnology · 2025Review
- Leukocyte Platelet-Rich Plasma-Derived Exosomes Restrained Macrophages Viability and Induced Apoptosis, NO Generation, and M1 Polarization.Immunity, inflammation and disease · 2024Article
- Incorporation of natural and synthetic polymers into honey hydrogel for wound healing: A review.Health science reports · 2024Article
- Recent Advances in Chitosan-Based Applications-A Review.Materials (Basel, Switzerland) · 2023Review
- Application of hydrogel wound dressings in cell therapy-approaches to assessment in vitro.International journal of burns and trauma · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study aimed to explore the clinical efficacy of chitosan-based hydrocolloid dressing in treating chronic refractory wounds. A total of 80 patients with chronic refractory wounds were randomly divided into the control group (n = 40) and the study group (n = 40). The control group was given inert saline gauze, while the study group was given chitosan-based hydrocolloid dressing. After 3 weeks of treatment, the wound healing efficiency, itching pain score, changes in the wound area, dressing change frequency, and cost were measured. There was a significant difference in the wound healing effect (t = 2.738), and degree of pain (t = 4.76) between the study and control groups, after 3 weeks of treatment. Similarly, a prominent reduction in the itching frequency (t = 8.62), and wound area (t = 6.379) was observed in the study group compared to the control group (P < .05). Moreover, the frequency and total cost of dressing change in the study group were also lower than the control group and the difference was statistically significant (P < .05). To summarise, the application of chitosan-based hydrocolloid dressing in treating chronic refractory can effectively alleviate pain, accelerate wound healing, relieve itching pain, and reduce the overall cost and frequency of dressing change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.